jumped Friday after
said new medical data showed its lung cancer drug Iressa provided no survival benefit in the overall population.
OSI's and Genentech's cancer drug Tarceva was recently approved by the Food and Drug Administration.
OSI gained $19.85, or 42%, to $66.95, while Genentech's rose $4.01, or 8.2%, to $52.50 in premarket trading.
AstraZeneca shares plunged $2.99, or 7.5%, to $36.70, a 52-week low, in the premarket. Its shares also fell sharply in European trading.
, which also markets a cancer drug, Erbitux, gained $1.82, or 4.1%, to $46.30.